ATE153345T1 - Behandlung polyzystischer ovarkrankheit - Google Patents

Behandlung polyzystischer ovarkrankheit

Info

Publication number
ATE153345T1
ATE153345T1 AT91909886T AT91909886T ATE153345T1 AT E153345 T1 ATE153345 T1 AT E153345T1 AT 91909886 T AT91909886 T AT 91909886T AT 91909886 T AT91909886 T AT 91909886T AT E153345 T1 ATE153345 T1 AT E153345T1
Authority
AT
Austria
Prior art keywords
treatment
polycystic
oval
disease
pcod
Prior art date
Application number
AT91909886T
Other languages
English (en)
Inventor
Bruno Lunenfeld
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909005958A external-priority patent/GB9005958D0/en
Priority claimed from GB909011823A external-priority patent/GB9011823D0/en
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE153345T1 publication Critical patent/ATE153345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT91909886T 1990-03-16 1991-03-14 Behandlung polyzystischer ovarkrankheit ATE153345T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909005958A GB9005958D0 (en) 1990-03-16 1990-03-16 Treatment of polycystic ovarian disease
GB909011823A GB9011823D0 (en) 1990-05-25 1990-05-25 Treatment of polycystic ovarian disease

Publications (1)

Publication Number Publication Date
ATE153345T1 true ATE153345T1 (de) 1997-06-15

Family

ID=26296796

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91909886T ATE153345T1 (de) 1990-03-16 1991-03-14 Behandlung polyzystischer ovarkrankheit

Country Status (11)

Country Link
EP (1) EP0472725B1 (de)
JP (1) JP3112172B2 (de)
AT (1) ATE153345T1 (de)
AU (1) AU647138B2 (de)
CA (1) CA2054686C (de)
DE (1) DE69126180T2 (de)
DK (1) DK0472725T3 (de)
ES (1) ES2102397T3 (de)
GR (1) GR3024225T3 (de)
IL (1) IL97571A (de)
WO (1) WO1991014704A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489288B1 (en) * 1990-03-16 2002-12-03 Applied Research Systems Ars Holding Treatment of polycystic ovarian disease
US6492177B1 (en) * 1990-03-16 2002-12-10 Applied Research Systems Ars Holding Nv Kit for use in treatment of polycystic ovarian disease
FI94181C (fi) * 1992-06-29 1995-07-25 Medix Biochemica Ab Oy Diagnostinen menetelmä synnytysajankohdan ennustamiseksi sekä siihen käytettävä reagenssipakkaus
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
DE19815060A1 (de) * 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK272789D0 (da) * 1989-06-02 1989-06-02 Novo Nordisk As Fremgangsmaade og praeparat til behandling af infertilitet

Also Published As

Publication number Publication date
EP0472725A1 (de) 1992-03-04
CA2054686C (en) 2007-09-25
WO1991014704A3 (en) 1991-11-14
WO1991014704A2 (en) 1991-10-03
JP3112172B2 (ja) 2000-11-27
AU647138B2 (en) 1994-03-17
AU7879791A (en) 1991-10-21
EP0472725B1 (de) 1997-05-21
DE69126180T2 (de) 1997-08-28
IL97571A0 (en) 1992-06-21
IL97571A (en) 1999-11-30
DE69126180D1 (de) 1997-06-26
JPH05501119A (ja) 1993-03-04
CA2054686A1 (en) 1991-09-17
DK0472725T3 (da) 1997-11-03
ES2102397T3 (es) 1997-08-01
GR3024225T3 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
EP0607297A4 (en) Hormone analogs with multiple ctp extensions.
ATE203166T1 (de) Protein-induzierende morphogenese
ES2009948A6 (es) Procedimiento de preparacion de una proteina procedente de una hormona estimulante folicular urinaria, mediante proceso de inmunopurificacion de un concentrado urinario post-menopausico.
BR9712488A (pt) Anticorpo anti-hm 1.24 humano remodelado
CA2032123A1 (fr) Dispositif de renfort et de soutien de la coiffe des rotateurs d'une articulation d'epaule d'individus
DE59203666D1 (de) Medizinische Zange.
NO954188D0 (no) Modifisert-protein- og -peptid - farmasöytika
MX9505249A (es) Agonistas de estrogeno.
VILAIN et al. Use of the flag flap for coverage of a small area on a finger or the palm: 20 years experience
EA200400427A1 (ru) Применение человеческого хорионического гонадотропина и лютеинизирующего гормона при контролируемой гиперстимуляции яичников
DE69126180D1 (de) Behandlung polyzystischer ovarkrankheit
RU2000129658A (ru) Способ терапевтического лечения бесплодия
ATE195339T1 (de) Antagonisten von wachstumshormonen
BR9106676A (pt) Peptideo,processo para promover a liberacao de niveis de hormonio de crescimento em um animal,composicao farmaceutica para promover a liberacao de niveis de hormonio de crescimento em animais,uso do composto e processo para promover a liberacao e elevacao de niveis de hormonio de crescimento no sangue
CA2074166A1 (en) Method for treating intestinal diseases
DE69738336D1 (de) Verwendung von keratinocyte growth factor-2
ES2119779T3 (es) Solubilizacion de proteinas en formas activas.
DE69334281D1 (de) TCF-II enthaltende medizinische Zusammensetzung
ATE110961T1 (de) Behandlung von beatmungsabhängigkeit mit wachstumshormon.
ATE337818T1 (de) Kannulationsanordnung
NO961995L (no) Anvendelse av IGF-BP for renaturering av IGF
KR900012622A (ko) 피부질환치료 조성물
DE60028682D1 (de) Wachstumhormone Inhibitoren Enthaltende pharmazeutische Zubereitungen oder ihre biologisch aktive Fragmente zur Behandlung von uterinen Myomas
RU94008752A (ru) Производные 3-ароилбензо(в)-тиофена, фармацевтическая композиция на их основе
Hong et al. Selective administration of human postexposure rabies prophylaxis for animal bite control at the US army in Korea

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee